111 results about "Drug formulations" patented technology

The invention relates to the technical field of medicine formulas, in particular to a fluralamide moxidectin composite drop and a preparation process thereof. The invention relates to a fluralan-moxidectin emulsion which is prepared from the following raw materials in percentage by mass: 26 to 30 percent of fluralan, 1.1 to 1.7 percent of moxidectin, 32 to 36 percent of solvent, 0.1 to 0.3 percent of butylated hydroxytoluene, 10 to 16 percent of polymer carrier and the balance of tetrahydrofuran polyethylene glycol ether. The coexisting drug is stabilized through the core-shell structure polymer carrier, phase separation is prevented, a neutral environment is maintained, long-acting stability is ensured, the transdermal absorption rate is optimized, skin irritation is reduced, and the synergistic drug effect is improved. Meanwhile, the slow release period of the medicine is prolonged, the metabolic interference and accumulated toxicity are reduced, and the dissolution efficiency and the skin mildness are both considered.

The present invention provides binary or ternary complexes capable of improving the stability of a drug, particularly inhibiting transesterification within a drug molecule. The compound can also improve the pharmacodynamic preparation performance of the medicine and improve the safety and effectiveness of the medicine.

The invention belongs to the technical field of biological medicine, and particularly relates to a CD44 / GSH dual-response eutectic drug delivery system and a preparation method thereof.The CD44 / GSH dual-response eutectic drug delivery system comprises a microneedle array composed of a biodegradable polymer matrix formed by hyaluronic acid (HA) and poly (lactic-co-glycolic acid) (PLGA), and the microneedle array comprises a plurality of microneedles; a microneedle comprising a pharmaceutical formulation of a resveratrol-berberine co-crystal integrated into the polymer matrix; wherein the polymer matrix comprises a disulfide bond that is a glutathione (GSH) responsive switch; wherein the hyaluronic acid is capable of specifically targeting a CD44 receptor; wherein the disulfide bond can be cleaved under the condition that the concentration of glutathione in a target tissue is increased, thereby releasing the resveratrol-berberine eutectic pharmaceutical formulation; and wherein the microneedle array is configured to percutaneously deliver the resveratrol-berberine co-crystal pharmaceutical formulation to the target tissue.

The invention discloses a medicine compatibility effective component analysis method, and relates to the technical field of medicine compatibility, and the method comprises the following steps: carrying out data integration based on pre-obtained patient basic information and traditional Chinese medicine prescription data to generate a comprehensive data set, extracting effective components from a preset unified component database to generate a component list, and storing the component list in a database; analyzing the acting target spots through preset target spot mapping to generate a target spot matrix; dynamically generating pathological weight parameters based on the target matrix and basic disease data of the patient, and predicting a pharmacological effect according to a target overlapping degree to generate an effect prediction result; based on the effect prediction result and the component list, a risk level evaluation coefficient is calculated by applying a risk weight algorithm, and then a risk level is obtained through decision making; based on the risk level, a compatibility effective component analysis report is generated, and the problem of limitation existing in the current medicine compatibility effective component analysis process is solved.

Described herein are systems and methods that combine at least three different detection modalities to characterize the stability of drug formulations, and sample plates for use with the systems and methods. The systems may include a clamp configured to apply a force to the sample plates that trap and pressurize air above an inlet and / or outlet of sample holders included in the sample plates. Measurements of various parameters of the samples may be obtained in tandem or simultaneously with a single instrument, which reduces sample volume requirements.

The disclosure provides for improved pharmaceutical compositions containing an active pharmaceutical ingredient and a non-polymeric lubricant and methods of manufacturing the same. In particular, the compositions are prepared using thermal processing or solvent spraying and provide improved properties as well as more efficient methods of manufacture.

The present invention represents a novel hybrid of the two natural products sclareol and doxorubicin, in the form of their conjugates. These compounds are in the form of conjugates wherein doxorubicin and sclareol are covalently linked by a linker in a molar ratio of 1: 1. The hybrid has been shown to have anti-cancer properties and is effective in the treatment of cancer cells resistant to a P-glycoprotein membrane transporter responsible for resistance to doxorubicin. Hybrid have been tested on different types of cell lines, including human glioblastoma, non-small cell lung cancer, and colorectal cancer. The invention further relates to a method for the production thereof and to the use thereof in pharmaceutical products or pharmaceutical preparations. The research results include the cytotoxic activity of single compounds, combined compounds, and conjugated compounds in sensitive and resistant cancer cell pairs with and without P-glycoprotein expression. The selectivity to cancer cells is determined by comparison with commercially available normal human lung fibroblasts. The study also studies the nanoparticle properties of the hybrids, their intracellular localization and in vivo toxicity.

An arylboron compound, its preparation method, applications, and pharmaceutical compositions are disclosed for tumor imaging. The compound of formula (I) exhibits high fluorescence quantum efficiency through intramolecular charge transfer. The compound of formula (I) synthesized in this invention can be linked to different antibodies via Q3 at certain concentrations, allowing for precise targeting of corresponding tumors based on the antibody. This type of boron drug formulation can be used in boron neutron capture therapy to kill tumor cells. It exhibits better killing effects; the compound of formula (I) targets tumor cells through antigen-antibody interaction. After the boron-10-containing drug accumulates at the tumor site, neutron radiation triggers a nuclear reaction releasing alpha particles and... 7 Lithium particles kill cells; the range of these two particles is approximately 10 μm. High-energy-density heavy ions disrupt the DNA double helix structure in tumor cells, causing irreparable cell death. Simultaneously, the 10 μm distance avoids damage to normal cells and tissues.

The invention relates to the technical field of biological medicine research and development, and discloses an intelligent research and development platform, system and method for network medicine of intelligent medicine. According to the method, an AI analysis module is utilized to construct a dynamic syndrome biological characteristic network based on clinical time sequence data; in combination with a time sequence dynamic syndrome biological simulation body, an evolutionary algorithm is executed through a data processing and control unit, and time sequence application and real-time monitoring are carried out on candidate network drug formulas. And the system evaluates the goodness of fit between a biological state path generated by each formula on the simulation body and an ideal recovery path based on a preset time sequence fitness function, and performs iterative evolution on a formula population through operations such as selection, crossover and variation until an optimal dynamic administration scheme is found. According to the method, the problem of network drug sequential optimization design is solved, an automatic closed-loop research and development system from data modeling to physical verification is constructed, and the efficiency and accuracy of drug research and development are improved.

Drug delivery devices and methods of controlled drug delivery to a patient are provided. The drug delivery device may include one or two microchip elements, each of which has a body portion with one or more drug release apertures in fluid communication with at least one containment reservoir. The drug release apertures are closed off by one or more reservoir caps which can be electrically activated to open the drug release apertures. The drug delivery device also includes (i) a drug formulation disposed in the at least one containment reservoir, and (ii) at least one drug-permeable membrane. In some cases, an outer housing is spaced a distance from an exterior wall of the body portion of the microchip element, the outer housing includes the at least one drug-permeable membrane, and a depot space is defined between the drug-permeable membrane and the exterior wall of the body portion of the microchip element.

The invention discloses an external application medicine formula for acute pancreatitis, and belongs to the field of traditional Chinese medicine preparation formulas, and the external application medicine formula for acute pancreatitis is prepared from the following raw materials in parts by weight: 1-2 parts of honeysuckle, 1-2 parts of wild chrysanthemum flower, 1-2 parts of dandelion, 1-2 parts of herba violae, 1 part of scutellaria baicalensis, 1 part of coptis chinensis, 1 part of raw rhubarb, 1 part of raw liquorice, 1 part of radix paeoniae rubra and 1 part of mangnolia officinalis. The traditional Chinese medicine composition can effectively reduce peripancreatic exudation and promote gastrointestinal motility, so that the symptoms of abdominal distension and abdominal pain of a patient are relieved, meanwhile, pancreatic microcirculation can be improved, disease recovery is facilitated, the preparation process is simple and easy to understand, complex equipment is not needed, and the production cost is greatly reduced.

The invention discloses a biological medicine active component screening method and system based on artificial intelligence, and relates to the technical field of biological medicine manufacturing. The method comprises the following steps: acquiring component characteristic parameters and performance parameters of a biological medicine formula to be optimized; constructing and acquiring a performance prediction model, and acquiring a performance prediction confidence coefficient based on the component characteristic parameters and the performance parameters; on the basis of the component features, obtaining an optimization feasible region in combination with the performance prediction confidence; performing iterative optimization in the optimization feasible region by adopting a particle swarm algorithm to obtain an optimized biological medicine formula, and obtaining optimized performance parameters of the optimized biological medicine formula based on the performance prediction model; and according to the optimized biological medicine formula and the optimized performance parameters, generating a biological medicine active component screening result. The screening efficiency and precision of the active ingredients of the biological medicine are effectively improved.

The invention relates to modified release oral formulations of therapeutic agents, including gamma hydroxybutyrate (GHB), paracetamol, codeine or oxycodone, which are resistant to alcohol induced dose dumping. Provided are formulations that have improved resistance to rapid release of the active ingredient in the presence of increasing amounts of alcohol. Also provided are formulations that can reduce or prevent the release of the active ingredient following exposure to alcohol-containing media. The invention also relates to methods of making the formulations, and methods of their use for the treatment of sleep disorders such as apnea, sleep time disturbances, narcolepsy, cataplexy, sleep paralysis, hypnagogic hallucination, sleep arousal, insomnia, and nocturnal myoclonus.

The invention relates to an formulation for cardiac support supplements and the method of its preparation by using molecular-level mixing technology. The method involves preparing molecular-level emulsions of alpha-lipoic acid, acetyl L-carnitine, and coenzyme Q10, followed by spray drying to produce a homogeneous powder premix. This approach ensures precise dosage control, enhanced bioavailability, and improved stability, making it a valuable advancement in the field of nutraceutical and pharmaceutical formulations.

The invention belongs to the technical field of biological medicines, and particularly relates to application of an ITGA6 inhibitor in preparation of a medicine for treating uveal melanoma. By integrating bioinformatics analysis of databases of TCGA, GTEx, CPTAC and the like, the invention systematically reveals that the ITGA6 has high specific expression in uveal melanoma and is significantly related to poor prognosis of a patient for the first time. In-vitro experiments prove that by knocking down ITGA6, proliferation, migration, invasion and colony forming ability of UVM cells can be effectively inhibited. According to the invention, small molecular compounds such as 4.5-diphenyl-1H-imidazole, MS-275, W-13 and the like and siRNA (small interfering Ribonucleic Acid) targeting ITGA6 are screened out to be used as effective inhibitors, and specific drug dosage forms such as intraocular injection and the like are provided. In addition, the ITGA6 inhibitor can be used in combination with a PD-1 / PD-L1 inhibitor, a CTLA-4 inhibitor or a chemotherapeutic drug to generate a synergistic anti-tumor effect. Mechanism research shows that ITGA6 promotes UVM progress by regulating a signal channel and a tumor immune microenvironment. The invention provides a new targeted treatment strategy for uveal melanoma, and has important clinical application value.

A drug supply unit (23) for an inhalation device (50), comprising a cartridge (1) containing a drug formulation solution (12), shall be provided. According to the invention, it comprises a housing (22, 22′, 22″, 22″′), in which the cartridge (1) is arranged so as to be displaceable in a longitudinal direction, the housing (22, 22′,22″, 22″) having a septum needle (26) in an end region, which, in an active position of the cartridge (1), pierces a septum (8) arranged at the distal end (6) of the cartridge (1) when the cartridge (1) is completely displaced in the longitudinal direction towards the end region, and having a releasable lock (34) which fixes the cartridge (1) in a passive position within the housing (22, 22′, 22″, 22″′) in such a way that the septum needle (26) is held at a distance from the septum (8).

The present invention provides drug delivery devices and methods for controlled drug delivery to a patient. The drug delivery devices can include one or two microchip elements, each having a body portion with one or more drug release apertures in fluid communication with at least one contained reservoir. The drug release apertures are closed by one or more reservoir covers that can be electrically activated to open the drug release apertures. The drug delivery devices further include (i) a drug formulation disposed in the at least one contained reservoir, and (ii) at least one drug permeable membrane. In some cases, an outer housing is spaced apart from an outer wall of the body portion of the microchip element, the outer housing includes the at least one drug permeable membrane, and defines a reservoir space between the drug permeable membrane and the outer wall of the body portion of the microchip element.

The invention provides a sustained-release medicinal preparation for preventing and treating alopecia as well as a preparation method and application of the sustained-release medicinal preparation, and belongs to the technical field of biological medicines. The medicine for preventing and treating alopecia is prepared from the following components: 1 to 2.5 mg of finasteride, 4 to 6 mg of minoxidil, 20 to 60 mg of spirolactone, 10 to 20 mg of isotretinoin, 3 to 8 mg of vitamin B5, 50 to 100 mg of zinc and 5 to 10 mg of vitamin b6. The components cooperate with one another to activate hair follicle stem cells, increase the number of hair follicles and synergistically enhance the ability of promoting hair regeneration, so that a better alopecia prevention and treatment effect is achieved; the pharmaceutical preparation prepared by selecting a specific filler, an adhesive, a sustained-release framework material and a lubricant in a reasonable proportioning range has good sustained-release performance, the dosage and frequency of the medicine are greatly reduced, and the side effect is far lower than that of an oral medicine in a common dosage form.

Orodispersible film (ODF) is an innovative drug formulation that allows for adjustable dosing and improved patient compliance. It is administered into the mouth where it dissolves, making it suitable for children. The present invention provides an optimized ODF gel formulation and an optimal ODF containing therapeutic doses of hydrocortisone-type corticosteroids (HTC). This ODF is thin, flexible and transparent, and suitable for production in hospital pharmacy using standard equipment. The ODF of the invention allows accurate hydrocortisone levels to be released systemically in patients in need thereof, and its good physico-chemical stability is herein demonstrated for several months. This opens up new opportunities for use in pediatric patients, notably for children suffering from congenital adrenal hyperplasia.

An analyte sensor, a preparation method and an application thereof are provided. The analyte sensor includes a sensing probe, an auxiliary needle and a drug formulation. The auxiliary needle includes a needle tip, a side wall and a bottom wall. The needle tip is connected to the bottom wall. An accommodating groove is defined by the side wall and the bottom wall connected to each other. The accommodating groove is configured to accommodate the sensing probe. The drug formulation is disposed on the auxiliary needle and / or on the sensing probe.

The present application relates to the technical field of pharmaceutical formulations, and particularly relates to a compound miconazole nitrate lotion and a preparation process thereof, which comprises the following raw materials in percentage by weight: miconazole nitrate 1.5-2.5%, amphiphilic polymer 5-6%, chlorhexidine gluconate 1.5-2.5%, casone 0.05-0.1%, benzoic acid 0.1-0.2%, surfactant 25-32%, PEG-120 methyl glucose dioleate 1-2%, citric acid monohydrate 0.3-0.4%, and sodium chloride 0.7-0.9%, and the rest is water. The compound miconazole nitrate lotion prepared by the present application has dual effects of anti-fungus and antibiosis, expands the scope of indications, enhances the overall antibacterial effect of the lotion, and is suitable for the treatment and prevention of various skin infections.

Drug formulations and methods for removing, reducing, or preventing the formation of fatty acid particles in drug formulations are provided.

The present disclosure described technology for developing long-acting injectable drug formulations. More specifically, the technology includes systems and methods for predicting a drug release profile in a patient. Importantly, the technologies provided herein enable substantially shortened development timelines for long-acting injectable drug formulations.

This invention discloses a biomimetic system simulating lung tissue, its manufacturing method, and a method for controlling microfluidics using this biomimetic system. The biomimetic system comprises lung epithelial cells, lung fibroblasts, and human umbilical vein endothelial cells isolated from human lungs, and is perfused with microfluidics. Gas and a fluid including culture medium can be perfused into the internal chambers of the system, simulating similar respiratory movements. Even after more than a week following perfusion, the three types of cells within the system can survive. Furthermore, pH and pO2 within the chambers can be monitored using pH and gas partial pressure sensors within the system, allowing the three types of cells to be exposed to the external environment or drugs under conditions similar to those of a living lung. This enables research in a wide range of fields, including modeling lung diseases caused by harmful substances and testing the efficacy of therapeutic drugs. It is also applicable to in vitro disease modeling and customized drug formulation.

The invention relates to an artificial vitreous humor composition comprising a phosphate buffer, wherein the phosphate buffer has a pH value in the range from 7.0 to 7.7, particularly from 7.1 to 7.6, more particularly from 7.2 to 7.5. The invention further relates to a method of production of an artificial vitreous humor composition, a method for analyzing the behavior of a substance, a method for analyzing the change of the artificial vitreous humor composition upon contact with a substance and a kit of parts.

An embodiment relates to systems and methods to deliver medications precisely within body of a subject as prescribed and tailored to individual needs. The system comprises a miniaturized implantable drug delivery device that dispenses drugs subcutaneously with controlled precision; a stable drug formulation that remains effective at body temperature; a biosensor that continuously monitors at least one of a drug level and health markers; and an analytics platform that analyses data to optimize drug delivery in real-time, ensuring highly personalized and effective patient care.

The invention discloses an inhalation device which comprises an inhaler main body, a suction nozzle, a tank assembly, a drying module and a counting module, and the inhaler main body is provided with a trigger surface; the suction nozzle is arranged on one side of the inhaler main body, and a discharge hole is formed in the suction nozzle; the tank assembly is movably arranged in the inhaler main body, the tank assembly is configured to press out mist, and an outlet of the tank assembly is communicated with the discharge hole; the drying module is arranged around the outlet of the tank assembly, and the drying module is configured to at least dry a channel of the outlet of the tank assembly when the suction device is in the storage state; the counting module is arranged at the tail part of the tank body, and the counting module is configured to be capable of being pressed by a user to move downwards to the triggering surface and cooperatively perform dose counting when the inhalation device is in a delivery state. According to the suction device, the drying chamber is arranged to perform moisture absorption treatment on the channel of the valve rod, so that deposition or accumulation of pharmaceutical preparations in the channel of the device is limited or basically eliminated, and the service life of the device is prolonged.

The invention relates to a medicine formula for repairing eardrum calcification and a preparation method. The collagen peptide III and the citric acid-chitosan conjugate are combined to realize combination of active repair and active decalcification, so that a repair material is provided, the problem of calcium salt deposition is solved from the pathogenesis, and both symptoms and root causes are treated. In-situ gelation and long-acting slow release of the medicine are realized by utilizing the temperature-sensitive hydrogel, the defect of short residence time of a traditional liquid preparation is overcome, and the availability and the treatment effect of the medicine are improved. Through the nanoemulsion, the penetrability of the medicine components to eardrum cuticle is remarkably improved, and it is ensured that the active components can effectively reach the focus. The citric acid-chitosan conjugate can be degraded, and citric acid is an intermediate product of tricarboxylic acid circulation in vivo and is high in safety. The anti-inflammatory component, the repairing component and the decalcification component have a synergistic effect to jointly create a microenvironment beneficial to tissue regeneration. The product can be administrated through ear dripping or tympanic chamber injection, so that the treatment pain of a patient is greatly reduced.

The invention relates to the technical field of body conditioning medicines, in particular to a medicine formula for conditioning a body movement system and a preparation process of the medicine formula. Comprising a main material and an auxiliary material, the main material is prepared by mixing the following raw materials by weight: 15-24 g of white peony root, 2-8 g of licorice, 4-12 g of achyranthes bidentata, 2-8 g of safflower, 5-15 g of dogwood, 5-12 g of prepared rehmannia root, 5-15 g of eucommia ulmoides, 2-10 g of fennel, 4-15 g of fructus aurantii and 15-25 g of folium artemisiae argyi; the auxiliary material is prepared by mixing the following raw materials by weight: 3-7 g of coix seed powder, 1-3 g of small red bean powder, 1-3 g of pea powder, 1-3 g of buckwheat powder, 1-3 g of Chinese yam powder, 1-3 g of soybean powder, 1-3 g of hyacinth bean powder, 8-12 g of Chinese wolfberry and 8-12 g of red dates. The formula has the beneficial effects that the formula is scientifically prepared, the nutrition is balanced, and diseases such as cervical spondylosis, chest, neck, waist and leg pains (chest, neck, waist and legs), protrusion of intervertebral disc, ankylosing spondylitis, arthritis, tennis elbow, rheumatic arthritis, femoral head necrosis, numbness of limbs, arthralgia, synovitis, knee effusion, meniscus injury, hyperostosis, sciatica and varicosity can be conditioned.

Liquid drug formulations must be frozen as part of the lyophilization process to remove the solvent via sublimation. This freezing process is typically done through shelf-based cooling. The present disclosure provides, in various aspects, forced convection gas cooling chamber that can be used with a continuous lyophilizer to freeze product in vials or other containers without requiring solid contact between the vials or other containers and another surface. The gas temperature can also change rapidly, and the present disclosure relates in various aspects to the implementation of a thermal quench method for controlled nucleation.